Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 401–500 of 1,001
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Salvatori, E., Lione, L., Compagnone, M., Pinto, E., Conforti, A., Ciliberto, G., Aurisicchio, L., & Palombo, F. (2022) · npj Vaccines · doi:10.1038/s41541-022-00433-9 · Cited by 57
Zhang, R., Tang, L., Tian, Y., Xiao, J., Hu, Q., Zhou, B., Zhenyu, D., Xu, H., & Yang, L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119852 · Cited by 53
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Janelle, V., Rulleau, C., Testa, S. D., Carli, C., & Delisle, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00276 · Cited by 59
“A significant contributor to the response against genetic variants is CD4 T-cell mediated, but most identified MiHA, TAA and TSA are MHC class I associated peptides (151).”
BackgroundTherapeutic vaccines for colorectal cancer: The progress and future prospect
Shahnazari, M., Samadi, P., Pourjafar, M., & Jalali, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106944 · Cited by 56
Neidert, M. C., Kowalewski, D. J., Silginer, M., Kapolou, K., Backert, L., Freudenmann, L. K., Peper-Gabriel, J. K., Marcu, A., Wang, S., Walz, J. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1836-9 · Cited by 56
Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy
Bulashevska, A., Nacsa, Z., Lang, F., Braun, M., Machyna, M., Diken, M., Childs, L. H., & König, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1394003 · Cited by 56
Self-citationConcepts in glioma immunotherapy
Platten, M., Bunse, L., Wick, W., & Bunse, T. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1874-x · Cited by 53
“We have acquired data, indicating that efficient killing requires activation of CD8+ T cells (unpublished data), which has been shown by others as well [43].”
BackgroundTargeting Head and Neck Cancer by Vaccination
Wang, C., Dickie, J., Sutavani, R. V., Pointer, C., Thomas, G. J., & Savelyeva, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00830 · Cited by 60
“Those specific for the target antigen Th1 cell subsets may be involved in recruitment of tumouricidal macrophages or reprogramming of the tumour microenvironment (100, 101).”
BackgroundPaul, S., Karosiene, E., Dhanda, S. K., Jurtz, V., Edwards, L., Nielsen, M., Sette, A., & Peters, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01795 · Cited by 50
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Neo approaches to cancer vaccines
Delamarre, L., Mellman, I., & Yadav, M. (2015) · Science · doi:10.1126/science.aab3465 · Cited by 57
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 52
“In fact, mutant MHC-II neoepitope vaccine elicited anti-tumor response in CD4+ T cell-dependent manner [57].”
BackgroundPhulphagar, K. M., Ctortecka, C., Jacome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100563 · Cited by 54
Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management
Rejali, L., Asl, R. S., Sanjabi, F., Fatemi, N., Aghdaei, H. A., Niasar, M. S., Moghadam, P. K., Mojarad, E. N., Mini, E., & Nobili, S. (2023) · Cancers · doi:10.3390/cancers15102746 · Cited by 54
“The majority of immunogenic neo-epitopes are class II-prohibited [106].”
BackgroundFeng, W., Shi, W., Cui, Y., Xu, J., Liu, S., Gao, H., Zhu, S., Liu, Y., & Zhang, H. (2023) · Theranostics · doi:10.7150/thno.81650 · Cited by 52
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era
Martin, S. D., Coukos, G., Holt, R. A., & Nelson, B. H. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv382 · Cited by 57
“The authors subsequently extended these results and found that neoantigenspecific CD4 T-helper cells were important mediators of the antitumor responses, and combining several mutant targets in a single vaccine improved survival of tumor-bearing mice [91].”
ResultImmunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 58
Bioengineered Nanocage from HBc Protein for Combination Cancer Immunotherapy
Shan, W., Zheng, H., Fu, G., Liu, C., Li, Z., Ye, Y., Zhao, J., Xu, D., Sun, L., Wang, X., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04722 · Cited by 50
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 53
Bystander CD4 + T cells infiltrate human tumors and are phenotypically distinct
Li, S., Zhuang, S., Heit, A., Koo, S., Tan, A. C., Chow, I., Kwok, W. W., Tan, I. B., Tan, D. S. W., Simoni, Y., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2012961 · Cited by 51
Maldonado, M. D. M., Schlom, J., & Hamilton, D. H. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03496-2 · Cited by 52
“[35] and are described in Supplementary Table 3.”
BackgroundMa, C., Zhang, Q., & Greten, T. F. (2017) · FEBS Journal · doi:10.1111/febs.14209 · Cited by 54
Challenges towards the realization of individualized cancer vaccines
Türeci, Ö., Löwer, M., Schrörs, B., Lang, M., Tadmor, A. D., & Şahin, U. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0266-2 · Cited by 51
Self-citationAn Update on Adoptive T-Cell Therapy and Neoantigen Vaccines
Ott, P. A., Dotti, G., Yee, C., & Goff, S. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238001 · Cited by 51
Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49
“The computational pipeline for identification of immunogenic CT26 neoantigens was reported previously.(13) For mutation detection, Strelka (version 2.”
BackgroundMethodInfluentialSelf-citationProgress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
Peng, P., Hu, H., Liu, P., & Xu, L. X. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000421 · Cited by 51
“…stresses induced by cryo-thermal therapy led to vastly increased tumor cell break-down; in addition, B16F10 melanoma has a high mutation burden, 21 and more neoantigens leaking out of broken tumor cells after cryo-thermal therapy were internalized, processed and presented on MHC-II molecules…”
InfluentialNeoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy
Li, Y., Fang, M., Yu, H., Wang, X., Xue, S., Jiang, Z., Huang, Z., Rong, S., Wei, X., Lu, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59977-8 · Cited by 55
“…whether the AECM@PC7A strategy could be applied to elicit neoantigen-speci fi c T-cell response, MC38 and CT26 murine colon cancer cells that without exogenous OVA were selected due to their well-characterised MHC-I restricted immunogenic neoantigens Adpgk & Rpl18 and AH1 & M19, respectively 47,48 .”
Yoshizaki, Y., Yuba, E., Komatsu, T., Udaka, K., Harada, A., & Kono, K. (2016) · Molecules · doi:10.3390/molecules21101284 · Cited by 48
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
Sato, Y., Bolzenius, J. K., Eteleeb, A. M., Su, X., Maher, C. A., Sehn, J. K., & Arora, V. K. (2018) · JCI Insight · doi:10.1172/jci.insight.121062 · Cited by 52
“used tumor sequencing and bioinformatic approaches to develop MHC class II antigen vaccines sufficient to induce CD4+ T cell–dependent therapeutic antitumor immunity (41).”
MethodBreakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy, S., Sethi, T. K., Taylor, D., Kim, Y. J., & Johnson, D. B. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0420-585rr · Cited by 49
Imodoye, S. O., Adedokun, K. A., & Bello, I. O. (2024) · Histochemistry and Cell Biology · doi:10.1007/s00418-023-02258-6 · Cited by 50
“The first understanding that personalized neoantigen vaccines can combat the full spectrum of the individual mutations in a patient’s tumor was proposed approximately 10 years ago (Kreiter et al. 2015; Castle et al.2012; Matsu-shita et al. 2012; Gubin et al. 2014).”
Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions
Radvanyi, L. G. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000162 · Cited by 56
“It has become apparent that less than 1% of mutations found in a tumor are so-called immunologically “actionable” in that they successfully induce a mutanome-specific clonal T-cell response.(122,129) The first obstacle to immune recognition is whether the mutation is monoallelic or biallelic and that if it is the form…”
BackgroundNeoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 49
PANDORA: A Fast, Anchor-Restrained Modelling Protocol for Peptide: MHC Complexes
Marzella, D. F., Parizi, F. M., Tilborg, D. V., Renaud, N., Sybrandi, D., Buzatu, R., Rademaker, D. T., ‘t Hoen, P. A. C., & Xue, L. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878762 · Cited by 44
Current tools for predicting cancer-specific T cell immunity
Gfeller, D., Bassani‐Sternberg, M., Schmidt, J., & Luescher, I. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1177691 · Cited by 47
“For personalized cancer vaccines based on TA peptides or corresponding RNA, in silico prediction and validation on patient’s T cells is an established but cumbersome strategy.(1,7,8,17,86-88,91)”
BackgroundCancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant
Overwijk, W. W. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.015 · Cited by 52
Bioinformatic methods for cancer neoantigen prediction
Boegel, S., Castle, J. C., Kodysh, J., O'Donnell, T., & Rubinsteyn, A. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.06.016 · Cited by 44
Self-citationKawashima, M., Carreras, J., Higuchi, H., Kotaki, R., Hoshina, T., Okuyama, K., Suzuki, N., Kakizaki, M., Miyatake, Y., Ando, K., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0737-9 · Cited by 46
Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery
Nuhn, L., Kaps, L., Diken, M., Schuppan, D., & Zentel, R. (2016) · Macromolecular Rapid Communications · doi:10.1002/marc.201600046 · Cited by 45
Self-citationMonitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice
Rosigkeit, S., Meng, M., Grunwitz, C., Gomes, P., Kreft, A., Hayduk, N., Heck, R., Pickert, G., Ziegler, K., Abassi, Y., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00370 · Cited by 42
Self-citationQuandt, J., Schlude, C., Bartoschek, M., Will, R. D., Arregui, A. C., Schölch, S., Reißfelder, C., Weitz, J., Schneider, M. A., Wiemann, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500671 · Cited by 45
Advancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 49
“TAA-induced cytokine responses are dependent on selective binding to MHC class II that suggests the role of CD4+ T cells rather than CD8+ T cells [85,86].”
BackgroundT follicular helper cells in cancer, tertiary lymphoid structures, and beyond
Cui, C., Craft, J. E., & Joshi, N. S. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101797 · Cited by 48
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Vormehr, M., Schrörs, B., Boegel, S., Löwer, M., Türeci, Ö., & Sahin, U. (2015) · Journal of Immunology Research · doi:10.1155/2015/595363 · Cited by 42
Self-citationTargeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 49
Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach
Kakwere, H., Ingham, E. S., Allen, R. P., Mahakian, L. M., Tam, S. M., Zhang, H., Silvestrini, M. T., Lewis, J. S., & Ferrara, K. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00502 · Cited by 44
“the peptides with polymers affords polymer-peptide conjugates that can be fabricated into nanoparticles via self-assembly thus ensuring that e majority of the immunostimulating peptide sequences identified during sequencing to develop personalized cancer vaccines can be utilized for personalized cancer treatment.(16,3…”
Chen, R., Fulton, K. M., Twine, S. M., & Li, J. (2019) · Mass Spectrometry Reviews · doi:10.1002/mas.21616 · Cited by 47
Aaes, T. L., Verschuere, H., Kaczmarek, A., Heyndrickx, L., Wiernicki, B., Delrue, I., Craene, B. D., Taminau, J., Delvaeye, T., Bertrand, M. J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900072 · Cited by 44
“Recently, it was demonstrated that the therapeutic immunogenic response to necroptosis can be driven by neoepitopes (59, 60).”
BackgroundMethodResultInfluentialHansen, U. K., Ramskov, S., Bjerregaard, A.-M., Borch, A., Andersen, R. S., Draghi, A., Donia, M., Bentzen, A. K., Marquard, A. M., Szállási, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00373 · Cited by 45
“Several cancer vaccines have shown to generate immune responses to class II neoepitopes either alone or in combination with class I neoepitopes (9, 53).”
BackgroundLiao, J.-Y., & Zhang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663264 · Cited by 48
Ellingsen, E. B., Aamdal, E., Guren, T. K., Lilleby, W. A., Brunsvig, P. F., Mangsbo, S. M., Aamdal, S., Hovig, E. J., Mensali, N., Gaudernack, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004345 · Cited by 49
“24 Cancer cells can also express HLA class II on IFN-γ stimulation, 25 providing a more direct target for CD4+ T cell-mediated cytotoxicity in immunogenic tumors.”
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 42
“Specific immune responses could be elicited and successful tumor shrinkage has been observed after application of neoantigen vaccines (67, 68, 76).”
BackgroundMayer, K. E., Mall, S., Yusufi, N., Gosmann, D., Steiger, K., Russelli, L., Bianchi, H. D. O., Audehm, S., Wagner, R., Bräunlein, E., et al. (2018) · Theranostics · doi:10.7150/thno.27275 · Cited by 46
“In this study, we performed an in-depth analysis for several pan T-cell-specific antibodies with the aim to identify one that does not modulate T-cell-related immune responses and would be suitable for diagnostic immuno-imaging with respect to immunotherapies potentially affecting different T-cell subpopulations [35-4…”
BackgroundMethodMachine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
Mösch, A., Raffegerst, S. H., Weis, M., Schendel, D. J., & Frishman, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01141 · Cited by 45
“(Linnemann et al., 2014; Kreiter et al., 2015; Tran et al., 2015; Hugo et al., 2016; Ott et al., 2017; Reuben et al., 2017; Sahin et al., 2017; Sonntag et al., 2018; Vrecko et al., 2018).”
BackgroundSchrörs, B., Hos, B. J., Yildiz, I., Löwer, M., Lang, F., Holtsträter, C., Becker, J., Vormehr, M., Şahin, U., OSSENDORP, F. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102282 · Cited by 45
Self-citationPoly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
Aurisicchio, L., Salvatori, E., Lione, L., Bandini, S., Pallocca, M., Maggio, R., Fanciulli, M., Nicola, F. D., Goeman, F., Ciliberto, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1084-4 · Cited by 45
“Starting from data in the literature [9, 23], we generated NAM expressing neoantigens from the B16 melanoma cell line (Fig.”
BackgroundMethodInfluentialAttacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00824 · Cited by 44
“These led to significant delay of tumor growth and protection of mice in a prophylactic (29) or therapeutic setting (29, 30).”
BackgroundDeepLigand: accurate prediction of MHC class I ligands using peptide embedding
Zeng, H., & Gifford, D. K. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz330 · Cited by 40
Immune Cycle‐Based Strategies for Cancer Immunotherapy
Li, Y., Liu, X., Zhang, X., Pan, W., Li, N., & Tang, B. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107540 · Cited by 45
Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects
Hyun, J., Jun, S., Lim, H., Cho, H., You, S.-H., Ha, S., Min, J.-J., & Bang, D. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00097 · Cited by 43
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective
Wang, C., Yu, M., & Zhang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215945 · Cited by 43
Chen, Y., Zhang, Y., Wang, B., Fan, Q., Yang, Q., Xu, J., Dai, H., Xu, F., & Wang, C. (2022) · ACS Nano · doi:10.1021/acsnano.2c10797 · Cited by 44
Schrörs, B., Lübcke, S., Lennerz, V., Fatho, M., Bicker, A., Wölfel, C., Derigs, P., Hankeln, T., Schadendorf, D., Paschen, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16048 · Cited by 43
Self-citationImmunotherapy approaches for the treatment of diffuse midline gliomas
Bernstock, J. D., Hoffman, S. E., Kappel, A. D., Valdes, P. A., Essayed, W. I., Klinger, N. V., Kang, K., Totsch, S. K., Olsen, H. E., Schlappi, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124058 · Cited by 44
“nificant fractions of non-synonymous tumor mutations are immunogenic and recognized by CD4 T cells, which help orchestrate and potentiate a systemic antitumor response.(84)”
BackgroundSun, G., Liu, H., Zhao, J., Zhang, J., Huang, T., Sun, G., Zhao, S., Zhang, Z., Cao, H., Rong, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005655 · Cited by 44
DNA Repair Deficiency and Immunotherapy Response
Mouw, K. W., & D’Andrea, A. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2425 · Cited by 43
Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors
Song, W., Das, M., Xu, Y., Si, X., Zhang, Y., Tang, Z., & Chen, X. (2019) · Materials Today Nano · doi:10.1016/j.mtnano.2019.100029 · Cited by 43
Hyperthermia and Tumor Immunity
Adnan, A., Muñoz, N. M., Prakash, P., Habibollahi, P., Cressman, E. N. K., & Sheth, R. A. (2021) · Cancers · doi:10.3390/cancers13112507 · Cited by 42
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 43
“The efficacy of neoantigen vaccines has also been confirmed in the mouse models of CRC [30, 65].”
BackgroundResultTherapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
Pao, S.-C., Chu, M.-T., & Chung, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040867 · Cited by 52
“reported that mutant MHC-class-II epitopes could drive CD4+ T-cell-mediated therapeutic immune responses to cancer [43].”
BackgroundShetty, S., Alvarado, P. C., Pettie, D., & Collier, J. H. (2024) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110122-124359 · Cited by 41
Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective
Liu, D., Liu, L., Li, X., Wang, S., Wu, G., & Che, X. (2024) · Vaccines · doi:10.3390/vaccines12080950 · Cited by 52
“Additionally, advanced genomic and proteomic technologies, like next-generation sequencing and mass spectrometry, play crucial roles in identifying potential antigens and validating their immunogenicity [64,65].”
BackgroundWang, B., An, J., Zhang, H., Zhang, S., Zhang, H., Wang, L., Zhang, H., & Zhang, Z. (2018) · Small · doi:10.1002/smll.201801372 · Cited by 40
Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development
Lancaster, E. M., Jablons, D. M., & Kratz, J. R. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0211 · Cited by 42
“From these data, they concluded that bioinformatics pipelines can be successfully used for neoantigen prediction in preclinical models (Kreiter et al. , 2015).”
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
Acebes-Fernández, V., Landeira‐Viñuela, A., Juanes‐Velasco, P., Hernández, Á., Otazo‐Pérez, A., Manzano-Román, R., Góngora, R., & Fuentes, M. (2020) · Nanomaterials · doi:10.3390/nano10071274 · Cited by 43
“Several studies have detected neoantigen-specific CD4+ T cells whose induction can control the tumour and, in murine models, the spread of antigen [344].”
BackgroundSelf‐Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy
Luo, Z., He, T., Liu, P., Yi, Z., Zhu, S., Liang, X., Kang, E. T., Gong, C., & Liu, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202002080 · Cited by 41
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002181 · Cited by 44
“Kreiter et al([83]) showed that neoantigen mRNA vaccines can induce cytotoxic T lymphocyte responses and reshape the tumor microenvironment associated with tumor control in mice.”
BackgroundClinical and Translational Advances in Glioma Immunotherapy
Bunse, L., Bunse, T., Krämer, C., Chih, Y., & Platten, M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01313-9 · Cited by 43
“The majority of neoantigens, however, are presented on MHC class II molecules, stimulating CD4+ T-helper cell responses [13, 14].”
BackgroundDeFrancesco, L. (2017) · Nature Biotechnology · doi:10.1038/nbt.3812 · Cited by 46
Challenges targeting cancer neoantigens in 2021: a systematic literature review
Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39
Hu, J., & Sun, J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1487914 · Cited by 39
Qin, L., Li, Q., Ren, J., Liu, W., & Jiang, G. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s325790 · Cited by 40
“In addition, mRNA-based neoantigens that can mobilize immunity against cancer mutations have been reported.(14,15)”
BackgroundMethodInfluentialSu, T., Liu, X., Lin, S., Cheng, F., & Zhu, G. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.02.016 · Cited by 50
Shin, H., Kim, Y., & Jon, S. (2023) · ACS Nano · doi:10.1021/acsnano.3c00764 · Cited by 41
Han, D., Wang, F., Ma, Y., Zhao, Y. F., Zhang, W., Zhang, Z., Liu, H., Yang, X., Zhang, C., Zhang, J., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01912 · Cited by 42
Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy
Zhang, Y., Zuo, B., Yu, Z., Zhao, K., Zhang, Y., He, K., Seow, Y., & Yin, H. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.021 · Cited by 40
Personalised neoantigen‐based therapy in colorectal cancer
Zhu, Y., Li, X., Chen, T., Wang, J., Zhou, Y., Mu, X., Du, Y., Wang, J., Tang, J., & Liu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1461 · Cited by 47
“97 Using three different tumour mouse models, Kreiter et al. 98 found that there were significant proportion of non-synonymous mutations in immune-related genes and most of these immune-related gene mutation products can be recognised by CD4 + T cells.”
BackgroundMethodYu, G., Li, Y., Cui, Z.-H., Morris, N. P., Weinberg, A. D., Fox, B. A., Urba, W. J., Wang, L., & Hu, H. (2016) · Scientific Reports · doi:10.1038/srep37558 · Cited by 39
Immunotherapy for Pediatric Brain Tumors
Sayour, E. J., & Mitchell, D. A. (2017) · Brain Sciences · doi:10.3390/brainsci7100137 · Cited by 38
“Unlike traditional pharmacologic agents that require increased titration for full effect (often with dose limiting toxicities that preclude rampant dose escalation), immunotherapy is a biologic agent that may not necessitate the same dose-dependent increases for maximal impact [22].”
BackgroundChuntova, P., Yamamichi, A., Chen, T., Narayanaswamy, R., Ronseaux, S., Hudson, C., Tron, A. E., Hyer, M. L., Montoya, M., Mende, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004644 · Cited by 39
“As such, direct extrapolation of the observed”
Pilotto, S., Molina‐Vila, M. Á., Karachaliou, N., Carbognin, L., Viteri, S., González‐Cao, M., Bria, E., Tortora, G., & Rosell, R. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.10.11 · Cited by 38
“Vaccination with synthetic polyneoepitope messenger RNA vaccines, produced against these carefully selected neoantigens, induces tumor rejection of established growing tumors in mice models (28).”
BackgroundOth, T., Vanderlocht, J., van Elssen, C. H. M. J., Bos, G. M. J., & Germeraad, W. T. V. (2016) · Mediators of Inflammation · doi:10.1155/2016/5740373 · Cited by 42
“Recently, the targeting of CD4 T cells by vaccination with a polytope mRNA vaccine (encoding immunogenic mutant class II epitopes) has been shown to be very efficient in mice by meditating strong antitumor responses [88].”
BackgroundJohanns, T. M., Bowman-Kirigin, J. A., Liu, C. J., & Dunn, G. P. (2017) · Neurosurgery · doi:10.1093/neuros/nyx321 · Cited by 42
Singh, N., Nand, S., Singh, V., & Singh, M. P. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101874 · Cited by 39
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 42
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 43
“Primary resistance, on the other hand, exists prior to exposure to the drug and prevents the drug from impeding tumor progression (85).”
BackgroundNanodrugs Targeting T Cells in Tumor Therapy
Haist, M., Mailänder, V., & Bros, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912594 · Cited by 38
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 49
“In 2015 , cationic lipids demonstrated successful delivery of mRNA expressing neo-antigens that can be recognised by CD4 + T cells, with complete rejection of established tumors in mice [106].”
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.